2019
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2015
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer
Dinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, Reed SD. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: 28-37.e2. PMID: 26382223, PMCID: PMC4698191, DOI: 10.1016/j.clgc.2015.07.006.Peer-Reviewed Original ResearchConceptsEnd Results-Medicare dataEnd of lifeProstate cancerOutpatient settingOutpatient useRetrospective analysisMore hospicesLower mean inpatient costsSkilled nursing facility daysIntensive care unit daysIntensive care unit useJudicious careAndrogen deprivation therapyOverall health care costsUse of chemotherapyMean inpatient costsMultiple invasive proceduresHealth care costsSignificant financial burdenDeprivation therapyNoncancer causesICU useSingle strongest predictorUnit daysInpatient costsLongitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer
Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. Journal Of Palliative Medicine 2015, 18: 933-939. PMID: 26241733, PMCID: PMC4638209, DOI: 10.1089/jpm.2015.0171.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancer metastasisRadiation therapyTreatment courseProstate cancerBony metastasesEnd Results-Medicare dataRadiation treatmentCancer metastasisCost-effective palliationPalliative radiation therapyPalliative radiation treatmentGeneral patient populationShort treatment courseHospital-based settingStudy inclusion criteriaTotal Medicare paymentsRadiation treatment courseRadiation therapy techniquesLack of evidencePalliative radiationPalliative settingPalliative treatmentClinical benefitPatient populationManagement of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. Journal Of The National Comprehensive Cancer Network 2015, 13: e1-7. PMID: 25583775, DOI: 10.6004/jnccn.2015.0014.Peer-Reviewed Original ResearchConceptsFebrile neutropeniaHigh riskNCCN Clinical Practice GuidelinesBroad-spectrum antibiotic treatmentCommon dose-limiting toxicityChemotherapy dose reductionsConsideration of prophylaxisLow-risk regimensDose-limiting toxicityChemotherapy-induced neutropeniaClinical practice guidelinesHealth care useEpisode of careMyeloid growth factorsGrowth factor useEarly treatment terminationHealth care costsPrimary prophylaxisMyelosuppressive chemotherapySupportive careSerious morbidityTreatment delayTherapeutic optionsAntibiotic treatmentCare use
2014
Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005. Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.Peer-Reviewed Original ResearchConceptsCell lung cancerTotal health care costsHealth care costsPositron emission tomographyProportion of patientsRate of surgeryMedicare beneficiariesLung cancerCare costsEmission tomographySurgical resectionInpatient costsRetrospective cohort studyYear of diagnosisMain outcome measuresCohort studyTreatment patternsOutcome measuresRadiation therapyChemotherapyPatientsRadiotherapyStudy periodCancerMedicare approval
2012
Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial
DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial. Value In Health 2012, 15: 277-283. PMID: 22433759, DOI: 10.1016/j.jval.2011.11.027.Peer-Reviewed Original ResearchConceptsLung functionMild impairmentCystic fibrosisClinical trialsAeruginosa colonizationHealth Utilities Index Mark 2/3Study case report formsPrimary end pointNationwide Inpatient SampleDirect medical costsMulticenter clinical trialP. aeruginosa colonizationPseudomonas aeruginosa colonizationMean annual costCase report formsLong-term useUtility estimatesEmergency visitsHospital admissionDornase alfaMedication costsRandomized trialsMean ageFemale sexInpatient Sample
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overDiagnostic ImagingFemaleHealth Care CostsHumansInsurance, Health, ReimbursementMaleMedicareNeoplasmsUnited StatesConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imaging
2009
Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement
Kamble S, Telen MJ, Dinan MA, Grussemeyer CA, Reed SD. Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. American Journal Of Hematology 2009, 85: 79-81. PMID: 20029954, PMCID: PMC2887617, DOI: 10.1002/ajh.21576.Peer-Reviewed Original Research